Nymox Pharmaceutical has received a delisting determination letter from Nasdaq for failing to meet the minimum bid price requirement. As a result, the company’s shares will be suspended from trading on Nasdaq starting July 7, 2023. Nymox’s common stock will be quoted on the OTC Markets after delisting. NYMX shares were down 14.3% in premarket trading.
- Nymox Pharmaceutical (NASDAQ:NYMX) informed shareholders on Wednesday that it has received a delisting determination letter from Nasdaq on failing to regain with the minimum bid price requirement.
- The deadline to regain compliance with Nasdaq listing requirements was July 3, 2023.
- The company’s shares will be suspended from trading on Nasdaq at the open of business on July 7, 2023.
- The company said its common stock will be quoted on the OTC Markets after delisting from Nasdaq.
- Shares of NYMX are down 14.3% in premarket trade on Thursday.
Source: SeekingAlpha